Skip to main
ACIU
ACIU logo

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is positioned favorably due to its innovative approach in targeting neurodegenerative diseases through advanced therapeutics that leverage proprietary technologies and focus on protein misfolding. The promising results from its PD active immunotherapy ACI-7104.056, which has shown a significant 20-fold increase in antibodies against pathogenic variants of aSyn, highlight the potential for impactful clinical advancements and successful upcoming trial readouts. Moreover, the ongoing NLRP3 program, particularly in conjunction with the positive expectations surrounding the EVOKE trial for Alzheimer's disease patients, suggests an increasing interest in the company's offerings, further solidifying a positive outlook for its future prospects.

Bears say

AC Immune SA concluded the quarter with a significant net operating loss of CHF 16.2 million, indicating financial stress. The company operates in a high-risk environment characterized by potential unfavorable clinical outcomes, regulatory uncertainties, and increasing complexity in pricing and market dynamics for its therapeutic candidates. These fundamental financial challenges, alongside the inherent risks associated with the biopharmaceutical industry, contribute to a negative outlook for AC Immune's stock.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.